was resuspended in 5% LPPG and 10% D 2 O, at pH 6.8. 2D HSQC spectra were collected and SR-BI(405-475) (black) and SR-BI(405-445) (blue) are overlayed. Residues corresponding to peaks with no/minimal shifting are highlighted in black, while residues corresponding to peaks with significant shifting are highlighted in red.
SUPPLEMENTAL EXPERIMENTAL PROCEDURES

Materials
The following antibodies were used: anti-SR-BI specific for the extracellular domain or the C-terminal cytoplasmic domain (Novus Biologicals, Inc.; Littleton, CO); anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Millipore; Billerica, MA); peroxidase-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch Laboratories; West Grove, PA); peroxidase-conjugated sheep anti-mouse (Amersham-GE Healthcare; Pittsburgh, PA). COS-7 cells were originally purchased from American Type Culture Collection (ATCC; Manassas, VA (Waltham, MA) . DNAse, Empigen, and n-dodecyl β-D-maltopyranoside (DDM) were purchased from Sigma-Aldrich. 1-palmitoyl-2-hydroxy-snglycero-3-phospho-(1'-rac-glycerol) (LPPG) was purchased from Avanti Polar Lipids, Inc (Alabaster, AL). Deuterated LPPG was purchased from FBReagents (Cambridge, MA). All other reagents were of analytical grade.
Cell culture and transfection
COS-7 cells were transiently transfected with Fugene 6 as previously described (Connelly et al., 1999b) . Cells were maintained in DMEM (Invitrogen) containing 10% calf serum (Invitrogen), 2 mM L -glutamine, 50 units/mL penicillin, 50 µg/mL streptomycin, and 1 mM sodium pyruvate. Cellular assays were performed 48 hours posttransfection, unless otherwise noted.
Cell surface expression
Cell surface expression of SR-BI was verified by flow cytometry similar to previously performed (Papale et al., 2011) . Briefly, cells were washed, released from the plate by trypsin, resuspended in PBS/0.5% bovine serum albumin (BSA) and incubated with an antibody directed against the extracellular domain of SR-BI (1:200 dilution) for 1 hour at 4°C. After washing, cells were resuspended in PBS/0.5% BSA and incubated with a FITC-conjugated goat anti-rabbit IgG antibody (1:1000) for 20 minutes at 4°C. Cells were then washed and resuspended in a PBS/0.5% BSA/1% paraformaldehyde solution and mean fluorescence intensities were analyzed using a FACS Calibur (Flow Cytometry Core, Medical College of Wisconsin) or an Accuri C6 (Blood Research Institute, Milwaukee, WI) equipped with a laser emitting at 488 nm. Using CFlow Plus software for analysis, gates excluding necrotic cells and cellular debris were set and fluorescence intensity of the gated region was measured. Data were collected from at least 10,000 events for each sample. Further gating of FITC fluorescent signal was performed so that empty-vector transfected cells accounted for approximately 0.5-2% total cells as baseline, thereby excluding cells adjacent to auto-fluorescent or non-transfected cells. Each independent experiment was gated by its respective empty-vector transfected control cells, and FITC relative mean fluorescence values were acquired for WT SR-BI or mutant receptors.
Plasmids for bacterial expression
Generation of plasmids for bacterial expression of SR-BI peptides is described (Chadwick et al., 2015) in Supplemental Experimental Procedures. Briefly, the sequence encompassing residues 405 to 475 of murine SR-BI cDNA was PCR-amplified and cloned into the BamHI and HindIII sites of a modified pQE30 vector (QIAGEN). The resulting plasmids encoded for a peptide with an N-terminal eight-residue histidine tag and tobacco etch virus (TEV) protease cleavage site, followed by SR-BI sequence corresponding to SR-BI residues 405-475 [herein referred to as SR-BI(405-475)]. A shorter peptide, , that encompasses residues 405-445, was also generated.
Purification of bacterially-expressed SR-BI constructs
Purification of bacterially-expressed SR-BI constructs was performed as previously described (Chadwick et al., 2015) . Briefly, following transformation of the plasmid encoding induced using 1 mM isopropyl-β-D-1-thiogalactopyranoside. Following centrifugation, cell pellets were resuspended in Buffer A (50 mM sodium phosphate, 300 mM sodium chloride, 10 mM imidazole, pH 7.4) containing lysozyme, 2-mercaptoethanol, protease inhibitor cocktail, DNAse, and RNase and were rocked, lysed, and solubilized with 10% empigen detergent. Lysate supernatant was applied to a gravity flow column containing nickel (His60 Ni Superflow) resin. Resin was washed 5x with Buffer A containing 1.5% empigen and protein was eluted using Buffer B (50 mM sodium phosphate, 300 mM sodium chloride, 500 mM imidazole, pH 7.4) containing 1.5% empigen. Protein was precipitated by excess addition of ammonium sulfate and the solution was centrifuged at 15,000 x g for 30 min. The resulting pellet was resuspended in Buffer A containing 6M guanidine HCl and 50 mM dithiothreitol and separated by reversed phase HPLC using a C18 column (column buffer of 70% acetonitrile, 30% 2-propanol, and 0.1% trifluoroacetic acid). Purified protein (expected mass of 10,778 Da) was confirmed by MALDI mass spectrometry, lyophilized, and stored at -80°C.
TEV protease cleavage was performed to remove the N-terminal tail containing the eight-residue histidine tag and tobacco etch virus cleavage site. SR-BI peptides were resuspended in a buffer containing 50 mM NaCl, 50 mM NaPO 4 , 0.5% DDM, 15 mM 2-mercaptoethanol, and TEV protease at pH 6.5 and rotated overnight. Following the incubation, the SR-BI peptides were separated by reversed phase HPLC using a C18 column. Purified protein (expected mass of 8269 Da) was confirmed by MALDI mass spectrometry, lyophilized, and stored at -80°C until used for NMR analysis.
NMR Analyses
NMR samples (0.5-1 mM SR-BI protein) were prepared in water containing 5% (w/v) LPPG, 10% (v/v) D 2 O, and 0.02% (v/v) sodium azide at pH 6.8, unless otherwise specified. Protein solubilization was aided by incubating the solution at 37-42°C and based on visual inspection, typically went into solution within 15 minutes after reconstitution into detergent micelles. Resonance assignments and distance constraints were obtained for SR-BI(405-475) using the following NMR experiments: 1 H-15 N-HSQC, HNCO, HN(CO)CA, HN(CO)CACB, HNCA, HNCACB, C(CO)NH, HCCH-TOCSY, HBHA(CO)NH, HC(CO)NH, 15 N-NOESY-HSQC, and 13 C-NOESY-HSQC (aromatic and aliphatic) NMR spectra (Mori et al., 1995; Muhandiram, 1994; Ziarek et al., 2011) were obtained at 40 ˚C on either a Bruker Avance III 500 MHz or Bruker 600 MHz spectrometer. A mixing time of 80 ms was used for all NOESY experiments. NMRPipe (Delaglio et al., 1995) was used for processing and data was analyzed using Xeasy (Bartels et al., 1995) . TALOS was used for determining Φ and Ψ dihedral angle constraints (Cornilescu et al., 1999) . CYANA was used (Herrmann et al., 2002) to generate the initial structures of SR-BI(405-475) and structures were further refined manually. Protein structure coordinates, NMR constraints and chemical shifts were deposited in the RCSB protein data bank and the BioMagResBank (PDB ID 5KTF; BMRB ID 30137).
